Lupin: The pharma company on Saturday said it has received two observations from the US health regulator following the inspection of its Nagpur manufacturing facility. A prior approval inspection was carried out by the United States Food and Drug Administration at the company's Nagpur oral solid dosage manufacturing facility between January 6-10, 2020, Lupin said in a filing to BSE.
POSITIVE